EUCTR2015-004813-26-ES进行中（未招募）1 期
ong Term Follow Up for Patients who have received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Anyone who has received a NiCord/CordIn transplant, signed the consent for this study, and completed study specific follow up.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 31
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient is not eligible if during the NiCord/CordIn transplant protocol, any of the following occurred before or on the completion of the last study visit (d365):
- •Disease relapse/progression
- •Autologous Recovery
- •Graft Failure
研究者
相似试验
招募中
1 期
ong-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)Kidney Transplant RejectionMedDRA version: 21.1Level: LLTClassification code: 10050436Term: Prophylaxis against renal transplant rejection Class: 10042613CTIS2024-512580-31-00Sangamo Therapeutics France30
尚未招募
不适用
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
进行中（未招募）
1 期
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2022-002440-40-DESangamo Therapeutics France SAS15
进行中（未招募）
1 期
ong-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.CTIS2024-511684-28-00Autolus Limited111
进行中（未招募）
1 期
ong-term follow-up of patients previously treated with an Autolus CAR T cell therapyEUCTR2016-004867-38-NLAutolus Limited500